SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Alon US 2006 Hypophosphatemic vitamin D-resistant rickets. In: FavusMJ (ed.) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 6th ed. The American Society for Bone and Mineral Research, Washington, DC, USA, 342345.
  • 2
    The Hyp Consortium 1995 A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11 : 130136.
  • 3
    Holm IA, Nelson AE, Robinson BG, Mason RS, Marsh DJ, Cowell CT, Carpenter TO 2001 Mutational analysis and genotype-phenotype correlation of the PHEX gene in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 86 : 38893899.
  • 4
    Sabbagh Y, Jones AO, Tenenhouse HS 2000 PHEXdb, a locus-specific database for mutations causing X-linked hypophosphatemia. Hum Mutat 16 : 16.
  • 5
    Beck L, Soumounou Y, Martel J, Krishnamurthy G, Gauthier C, Goodyer CG, Tenenhouse HS 1997 Pex/PEX tissue distribution and evidence for a deletion in the 3′ region of the Pex gene in X-linked hypophosphatemic mice. J Clin Invest 99 : 12001209.
  • 6
    Strom TM, Francis F, Lorenz B, Boddrich A, Econs MJ, Lehrach H, Meitinger T 1997 Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia. Hum Mol Genet 6 : 165171.
  • 7
    Meyer RA Jr, Meyer MH, Gray RW 1989 Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia in mice. J Bone Miner Res 4 : 493500.
  • 8
    Nesbitt T, Coffman TM, Griffiths R, Drezner MK 1992 Crosstransplantation of kidneys in normal and Hyp mice. Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect. J Clin Invest 89 : 14531459.
  • 9
    The ADHR Consortium 2000 Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26 : 345348.
  • 10
    Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98 : 65006505.
  • 11
    Bai X, Miao D, Li J, Goltzman D, Karaplis AC 2004 Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145 : 52695279.
  • 12
    Bai XY, Miao D, Goltzman D, Karaplis AC 2003 The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278 : 98439849.
  • 13
    Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, Jonsson KB 2004 Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145 : 30873094.
  • 14
    Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T 2004 FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19 : 429435.
  • 15
    Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2002 Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143 : 31793182.
  • 16
    Araya K, Fukumoto S, Backenroth R, Takeuchi Y, Nakayama K, Ito N, Yoshii N, Yamazaki Y, Yamashita T, Silver J, Igarashi T, Fujita T 2005 A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 90 : 55235527.
  • 17
    Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T 2004 Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113 : 561568.
  • 18
    Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Juppner H, Lanske B 2004 Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23 : 421432.
  • 19
    Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H 2003 Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348 : 16561663.
  • 20
    Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S 2002 Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87 : 49574960.
  • 21
    Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD 2006 Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 291 : E38E49.
  • 22
    Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD 2003 Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278 : 3741937426.
  • 23
    Liu S, Tang W, Zhou J, Vierthaler L, Quarles LD 2007 Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. Am J Physiol Endocrinol Metab 293 : E1636E1644.
  • 24
    Yamazaki Y, Tamada T, Kasai N, Urakawa I, Aono Y, Hasegawa H, Fujita T, Kuroki R, Yamashita T, Fukumoto S, Shimada T 2008 Anti-FGF23 neutralizing antibodies demonstrate the physiological role and structural features of FGF23. J Bone Miner Res 23 : 15091518.
  • 25
    Tahara T, Kuwaki T, Matsumoto A, Morita H, Watarai H, Inagaki Y, Ohashi H, Ogami K, Miyazaki H, Kato T 1998 Neutralization of biological activity and inhibition of receptor binding by antibodies against human thrombopoietin. Stem Cells 16 : 5460.
  • 26
    Tenenhouse HS, Beck L 1996 Renal Na(+)-phosphate cotransporter gene expression in X-linked Hyp and Gy mice. Kidney Int 49 : 10271032.
  • 27
    Yuan B, Takaiwa M, Clemens TL, Feng JQ, Kumar R, Rowe PS, Xie Y, Drezner MK 2008 Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest 118 : 722734.
  • 28
    Baum M, Loleh S, Saini N, Seikaly M, Dwarakanath V, Quigley R 2003 Correction of proximal tubule phosphate transport defect in Hyp mice in vivo and in vitro with indomethacin. Proc Natl Acad Sci USA 100 : 1109811103.
  • 29
    Prie D, Blanchet FB, Essig M, Jourdain JP, Friedlander G 1998 Dipyridamole decreases renal phosphate leak and augments serum phosphorus in patients with low renal phosphate threshold. J Am Soc Nephrol 9 : 12641269.
  • 30
    Tenenhouse HS, Martel J, Rubin J, Harvey N 1994 Effect of phosphate supplementation on the expression of the mutant phenotype in murine X-linked hypophosphatemic rickets. Bone 15 : 677683.
  • 31
    Bai X, Miao D, Goltzman D, Karaplis AC 2007 Early lethality in Hyp mice with targeted deletion of Pth gene. Endocrinology 148 : 49744983.
  • 32
    Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro OM, Mohammadi M, Sirkis R, Naveh-Many T, Silver J 2007 The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117 : 40034008.
  • 33
    Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson KB, Westin G, Larsson TE 2007 Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195 : 125131.
  • 34
    Sitara D, Kim S, Razzaque MS, Bergwitz C, Taguchi T, Schuler C, Erben RG, Lanske B 2008 Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet 4 : e1000154.
  • 35
    Wang H, Yoshiko Y, Yamamoto R, Minamizaki T, Kozai K, Tanne K, Aubin JE, Maeda N 2008 Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 23 : 939948.
  • 36
    Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M 2006 Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281 : 61206123.
  • 37
    Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T 2006 Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444 : 770774.
  • 38
    Marie PJ, Travers R, Glorieux FH 1982 Bone response to phosphate and vitamin D metabolites in the hypophosphatemic male mouse. Calcif Tissue Int 34 : 158164.
  • 39
    Ono T, Tanaka H, Yamate T, Nagai Y, Nakamura T, Seino Y 1996 24R,25-dihydroxyvitamin D3 promotes bone formation without causing excessive resorption in hypophosphatemic mice. Endocrinology 137 : 26332637.